Innovations in Nuclear Imaging Instrumentation: Cerenkov Imaging. Review uri icon

Overview

abstract

  • Cerenkov luminescence (CL) is blue glow light produced by charged subatomic particles travelling faster than the phase velocity of light in a dielectric medium such as water or tissue. CL was first discovered in 1934, but for biomedical research it was recognized only in 2009 after advances in optical camera sensors brought the required high sensitivity. Recently, applications of CL from clinical radionuclides have been rapidly expanding to include not only preclinical and clinical biomedical imaging but also an approach to therapy. Cerenkov Luminescence Imaging (CLI) utilizes CL generated from clinically relevant radionuclides alongside optical imaging instrumentation. CLI is advantageous over traditional nuclear imaging methods in terms of infrastructure cost, resolution, and imaging time. Furthermore, CLI is a truly multimodal imaging method where the same agent can be detected by two independent modalities, with optical (CL) imaging and with positron emission tomography (PET) imaging. CL has been combined with small molecules, biomolecules and nanoparticles to improve diagnosis and therapy in cancer research. Here, we cover the fundamental breakthroughs and recent advances in reagents and instrumentation methods for CLI as well as therapeutic application of CL.

publication date

  • March 16, 2018

Research

keywords

  • Inventions
  • Nuclear Medicine
  • Optical Imaging

Identity

PubMed Central ID

  • PMC6251708

Scopus Document Identifier

  • 85043991998

Digital Object Identifier (DOI)

  • 10.1053/j.semnuclmed.2018.02.007

PubMed ID

  • 29852945

Additional Document Info

volume

  • 48

issue

  • 4